welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
- log in
John L. Jefferies, MD, MPH, FACC, FAHA, FHFSA
University of Tennessee Health Science Center
A312 Coleman Building
956 Court Avenue
Memphis, Tennessee, United States
In 2018, John L. Jefferies has been appointed the Jay M. Sullivan Endowed Chair in Cardiovascular Medicine and Chief of Cardiology at the University of Tennessee Health Science Center (UTHSC). He has also been named co-director for UT Methodist Institute for Cardiovascular Science.
Dr. Jefferies graduated from UT Knoxville with a degree in microbiology in 1992 and acquired his medical degree from UTHSC in 1996. He then completed an internship and residency in internal medicine and pediatrics at the University of Kentucky followed by adult and pediatric cardiology (combined) training at Baylor College of Medicine in Houston, TX. Dr. Jefferies has served for more than eight years at the University of Cincinnati College of Medicine and Cincinnati Children’s, where he was an associate professor of adult cardiovascular disease and pediatric cardiology from 2010-2015, professor of adult cardiovascular disease and pediatric cardiology from 2015-2018, and professor of human genetics from 2015-2018.
His research interests include novel gene discovery for various forms of cardiomyopathy, quality-of-life research in cardiomyopathy and heart failure, cardio-oncology, cardiac care in genetic syndromes, and novel drug investigation in heart failure.
other Duchenne content
Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular DystrophyThe objective is to determine whether ne...
Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical tri...Duchenne muscular dystrophy (DMD) is an ...
Solid Biosciences Provides Update Regarding the IGNITE DMD Phase I/II Clinical HoldSolid Biosciences Inc., a life sciences ...
An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy who Participated in Studies of SRP-5051The purpose of this extension study is t...
Eteplirsen, a Phosphorodiamidate Morpholino Oligomer (PMO) for Duchenne Muscular Dystrophy (DMD): Clinical Update an...Objective: DMD, a rare, degenerative, X...
Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dyst...Duchenne Muscular Dystrophy (DMD) is inh...
Erika Finanger, MDDr. Erika Finanger is a specialized pedi...
Kathryn Wagner, MD, PhD – Progress in Better Treatments for Muscular Dystrophyhttps://www.youtube.com/watch?v=0yC4_lEn...